Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a ‘Buy’ Rating from Needham
We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci Corporation (ABSI): AI in Biopharma Discovery
We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...
AbSci’s Strategic Partnerships and Strong Financial Position Justify Buy Rating
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...
Investing9d
Absci stock reiterated at Buy at H.C. Wainwright on AI-drug discovery leadership
The endorsement comes after a recent investor breakfast where Absci's management team discussed the company's competitive edge in the AI-drug discovery sector. Absci's management, including CFO ...
ADVFN11d
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery.
Investing4d
Needham initiates Absci shares with Buy rating on strategy
In other recent news, Absci Corp has been making significant strides in its AI-drug discovery sector. The company's earnings and revenue potential were highlighted by H.C. Wainwright, which ...
Investing9d
Absci stock reiterated at Buy at H.C. Wainwright on AI-drug discovery leadership
The endorsement comes after a recent investor breakfast where Absci's management team discussed the company's competitive edge in the AI-drug discovery sector. Absci's management, including CFO and ...